Image source: Getty Images
Neuren Pharmaceuticals vs Telix Pharmaceuticals shares
If you're an Aussie investor with an eye on the booming healthcare sector, chances are you've heard the buzz around Neuren Pharmaceuticals Ltd (ASX: NEU) and Telix Pharmaceuticals Ltd (ASX: TLX). Both companies have delivered innovative breakthroughs—one in neurological disorders, the other in targeted cancer diagnostics and therapy—and have captured strong market interest in recent years. But with some striking differences in their fundamentals, income appeal, and share price momentum, which healthcare stock is the better buy right now?
The case for Neuren Pharmaceuticals
Neuren Pharmaceuticals is a biotechnology company specialising in developing novel treatments for rare neurodevelopmental disorders, particularly those that affect children. Its flagship drug, DAYBUE (trofinetide), was approved by the US FDA in March 2023 as the first ever treatment for Rett syndrome, and is licensed in the US through Acadia Pharmaceuticals. According to its recent company profile, DAYBUE remains the only approved therapy for this indication. Neuren is also progressing trials of new candidates targeting additional syndromes, signalling a vibrant pipeline.
A few key fundamentals stand out:
- Neuren's market cap sits at $2.60 billion, making it a sizeable but nimble biotech.
- It has begun generating earnings (EPS 0.154), but its P/E ratio is a lofty 131.95—which is very high even for biotechs, reflecting both growth optimism and risk.
- Uniquely among many peers, Neuren actually pays a dividend: its current yield is 0.74%, with full (100%) franking reported on its latest interim payout of $0.15 per share.
That rare combination of cutting-edge drug development, early earnings, and a dividend (albeit modest) gives Neuren a distinctive profile for income-hunting investors interested in the healthcare sector.
The case for Telix Pharmaceuticals
Telix Pharmaceuticals is another home-grown biotech success story, but with a different therapeutic focus. Telix develops and commercialises theranostic (diagnostic and therapeutic) products using targeted radiation, with emphasis on treating and imaging cancers such as prostate, kidney, and brain tumours. The company's prostate cancer imaging agent, Illuccix, already has approvals in Australia, the US, and Canada, with the UK and Europe also on its radar. Telix boasts a substantial pipeline, with over 20 clinical trials underway across multiple countries and therapeutic areas.
Key Telix fundamentals from the dataset:
- Telix's market cap is $5.93 billion—more than double Neuren's—marking it as one of the sector's heavyweights on the ASX.
- It's also generating positive earnings (EPS 0.099), and its P/E ratio is 121.97 – Like Neuren, this figure is very high compared to the broader market.
- However, Telix does not offer a dividend at present—its yield is 0%—which is fairly standard for a rapidly reinvesting biotech but removes any immediate income appeal.
Telix's size and global reach, plus its diverse late-stage pipeline, make it an intriguing candidate for growth investors focused on healthcare innovation.
Valuation comparison
Since both companies are ASX-listed healthcare innovators of comparable maturity, the core valuation metrics stack up as follows:
| Metric | Neuren Pharmaceuticals | Telix Pharmaceuticals |
| Market Cap | $2.60 billion | $5.93 billion |
| P/E Ratio | 131.95 | 121.97 |
| EPS | 0.154 | 0.099 |
| Dividend Yield | 0.74% (100% franked) | 0.00% |
| Year To Date Return | 10.2% | 50.6% |
Note: Both companies' P/E ratios are extremely high relative to the general market, which is typical for biotech stocks where earnings are newly positive and future growth is heavily priced in. Also, while both have positive EPS, the relationship between reported EPS and the stated P/E may be based on different earnings definitions (trailing, underlying, or forecast), so the exact calculation might not match.
Recent share price performance
Looking at the past month: 19 August to 17 September 2026.
- Neuren Pharmaceuticals shares rose from $22.85 to $20.54 over this period—so, a decline, with notable volatility (including a single-day drop of 10.6%).
- Telix Pharmaceuticals, in contrast, jumped from $16.84 to $17.45, including several days of strong upward moves (up as much as 8.6% in a day).
- Year to date, Neuren is up 10.2%, while Telix leads with a 50.6% return.
- Only Neuren has paid a recent dividend (ex-date 15 Sep 2026, $0.15 per share, fully franked).
Which is the better buy?
While both Neuren Pharmaceuticals and Telix Pharmaceuticals are stellar examples of Aussie healthcare innovation, I'd lean toward Telix Pharmaceuticals as the better buy right now. The verdict comes down to sheer momentum and growth potential—Telix's YTD return of 50.6% absolutely crushes Neuren's 10.2%, and the recent price charts show Telix enjoying much stronger investor confidence. Both sport very high P/E ratios, but Telix's rapid expansion into global cancer markets and its larger scale tip the balance for me, even without a dividend.
Neuren deserves credit for delivering both earnings and a small (but fully franked) dividend at such an early growth stage, which will appeal to income collectors who value some extra yield from their healthcare allocations. But if I had to pick between the two for exposure to biotech upside, Telix's global opportunity, ongoing clinical advancements, and share price trajectory look more compelling.
Of course, biotech investing always carries risk, and these companies' high valuations reflect market excitement about a promising—but not guaranteed—future. But based on the available data, my pick would be Telix Pharmaceuticals for investors seeking strong recent growth and commercial momentum in healthcare.
